Bausch Health Companies Inc.

NYSE:BHC

Drug Manufacturers - Specialty & Generic

Healthcare
$8.73 -2.21%

-$0.11 today

Market cap
$3.27B
Beta
0.41
P/E (TTM)
-1.5
EPS (TTM)
-$3.19
52W Low $4.57High $8.69

Volume 6.83M

Average 1.70M

BHC Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Bausch Health Companies Inc.NYSE: BHC

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization declines year over year

Q2 FY2026 depreciation & amortization of $281M fell 8.5% year over year, behind the -5.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.7% from the prior quarter. Over 3 fiscal years it compounded at -4.7% a year.

Context

  • Depreciation & amortization amounted to 11.8% of revenue in FY2025, down 1.4 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -8.5% toward the trailing-twelve-month pace of -5.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$281M-4.7% QoQ
Last fiscal yearDec 2025
$1.21B-4.7% YoY
LTMJun 2026
$1.17B-5.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.5%——
1 year-4.7%——
3-year CAGR-4.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
1.21B USD
Year-over-year change
-4.7%
4-year CAGR
-6.1%

Depreciation & Amortization vs competitors

How BHC compares with its peers on the latest reported figures

  • BHC's LTM Jun 2026 depreciation & amortization of $1.17B is the highest of the 11 companies compared; the peer median is $59.13M.
  • Its year-over-year change of -5.6% is the 10th highest of 11, against a peer median of +2.1%.
  • Depreciation & amortization amounts to 10.8% of revenue for BHC, versus a peer median of 8.1%.
BHC Competitors Peer median
Depreciation & Amortization for BHC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BHCBausch Health Companies Inc.LTM Jun 2026$1.17B -5.6%-4.7%10.8%
PRGOPerrigo Company plcLTM Jun 2026$403.5M +22.7%-0.1%9.7%
XRAYDENTSPLY SIRONA Inc.LTM Mar 2026$352M +2.9%+2.4%9.6%
HAEHaemonetics CorporationLTM Jun 2026$110.07M -4.5%+6.2%8.1%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$89.45M +17.8%+15.3%9.7%
CONConcentra Group Holdings Parent, Inc.LTM Sep 2026$79.99M +12.4%+1.0%3.4%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026$38.26M +1.2%+212.7%6.4%
ALVOAlvotechLTM Mar 2026$31.92M -1.4%+22.9%5.7%
BEAMBeam Therapeutics Inc.LTM Jun 2026$22.24M +1.2%+16.4%14.3%
HCMHUTCHMED (China) LimitedLTM Jun 2025$12.21M +14.7%+15.5%2.0%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$39K -31.6%——
Peer median (excluding BHC) $59.13M+2.1%+15.3%8.1%

Competitors are the stored peer set for BHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue8.43B8.12B8.76B9.63B10.27B
Cost of Revenue2.39B2.36B2.56B2.78B3.01B
Gross Profit6.04B5.76B6.2B6.84B7.25B
Gross Margin71.6%70.9%70.8%71.1%70.7%
Research & Development473M530M604M634M629M
Selling, General & Admin2.49B2.53B2.9B3.28B3.44B
Operating Expenses5.59B5.31B5.24B5.3B5.07B
Depreciation & Amortization1.55B1.39B1.26B1.27B1.21B
EBITDA3.26B2.88B2.89B3.13B3.18B
EBITDA Margin38.7%35.4%32.9%32.6%31.0%
Operating Income450M454M963M1.55B2.19B
Operating Margin5.3%5.6%11.0%16.1%21.3%
Interest Income7M14M26M33M48M
Interest Expense1.43B1.46B1.33B1.39B1.6B
Other Income / Expenses(1.47B)(583M)(1.35B)(1.38B)(1.82B)
Income Before Tax(1.02B)(129M)(390M)167M367M
Pre-Tax Margin-12.1%-1.6%-4.5%1.7%3.6%
Income Tax Expense(87M)83M221M239M247M
Net Income(948M)(225M)(592M)(46M)157M
Net Margin-11.2%-2.8%-6.8%-0.5%1.5%
EPS (Basic)(2.61)(0.62)(1.62)(0.13)0.43
EPS (Diluted)(2.61)(0.62)(1.62)(0.13)0.43
Weighted Avg Shares358.9M362M364.9M368M370.9M
Weighted Avg Shares (Diluted)358.9M362M364.9M368M375M

Bausch Health Companies Inc.

NYSE:BHC

Intrinsic Alpha fair value

Locked

Current Price

$8.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.